The 2014 Bernard B. Brodie Award Lecture

Epoxide Hydrolases: Drug Metabolism to Therapeutics for Chronic Pain

Kodani, S.D. and B.D. Hammock

Department of Entomology and Nematology and Comprehensive Cancer Center, University of California, Davis, Davis, CA 95616 (S.D.K., B.D.H.)
DMD # 63339

**Running Title:** Epoxide Hydrolases: Drug Metabolism to Therapeutics

**Corresponding Author:**
Bruce D. Hammock, Ph.D., Department of Entomology, University of California, Davis, Davis, CA 95616, FAX: 1 530 752 1537, Email: bdhammock@ucdavis.edu

**Text Pages:** 23

**Tables:** 2

**Figures:** 8

**References:** 174

**Abstract Word Count:** 157

**Introduction Word Count:** 573

**Discussion Word Count:** 6,671

**Abbreviations and definitions:** ACPU, 1-(Adamantan-1-yl)-3-(1-(2-(7-hydroxy-2-oxo-2H-chromen-4-yl)acetyl)piperidin-4-yl)urea; ARDS, Acute Respiratory Distress Syndrome; AUDA, 12-(3-Adamantan-1-yl-ureido)-dodecanoic acid; CDU, 1-cyclohexyl-3-dodecyl urea; ChEH, Cholesterol Epoxide Hydrolase; CMNPO, Cyano(6-methoxy-naphthalen-2-yl)methyl trans-[3-phenyloxiran-2-yl]methyl] carbonate; COPD, Chronic Obstructive Pulmonary Disorder; DiHOME, Dihydroxyoctadecenoic Acid; EET, Epoxyeicosatrienoic Acid; EpDPE, Epoxydocosapentaenoic Acid; EpETE, Epoxyeicosatetraenoic Acid; EpOME, Epoxyoctadecenoic Acid; ER, Endoplasmic Reticulum; FAAH, Fatty Acid Amide Hydrolase; GLC, Gas-liquid chromatography; HEOM, 1,2,3,4,9,9-Hexachloro-6,7-epoxy-1,4,4a,5,6,7,8,8a-octahydro-1,4-methanonaphthalene; IND, Investigational New Drug; mEH, Microsomal Epoxide Hydrolase; NSAIDs, Non-stereoidal Anti-inflammatory Drugs; sEH, Soluble Epoxide Hydrolase; t-DPPO, trans-Diphenylpropene Oxide
Bernard Brodie’s legacy is built on fundamental discoveries in pharmacology and drug metabolism that were then translated to the clinic to improve patient care. Similarly, the development of a novel class of therapeutics termed the soluble epoxide hydrolase (sEH) inhibitors was originally spurred by fundamental research exploring the biochemistry and physiology of the sEH. Here, we present an overview of the history and current state of research on epoxide hydrolases, specifically focusing on sEH. In doing so, we start with the translational project studying the metabolism of the insect juvenile hormone mimic R-20458 which led to the identification of the mammalian sEH. Further investigation of this enzyme and its substrates, including the epoxyeicosatrienoic acids, led to insight into mechanisms of inflammation, chronic and neuropathic pain, angiogenesis and other physiological processes. This basic knowledge in turn led to the development of potent inhibitors of the sEH that are promising therapeutics for pain, hypertension, COPD, arthritis and other disorders.
INTRODUCTION

Discovery comes in many colors and flavors. The discovery process is driven by multiple motivations ranging from agency goals to personal quests, with outcomes that can be labeled as basic or applied, fundamental or translational. Our field of xenobiotic metabolism is often seen as an applied field, yet it has repeatedly led to fundamental insight. The work of Dr. Bernard Brodie illustrates that our field was inspired by the need for improved therapeutics (Bickel, 1989; Costa et al., 1989). As improved therapeutics are delivered, we learn more about xenobiotic metabolism with surprises along the way that provide basic insights into physiologic and biochemical mechanisms. This paper follows the metabolic study of a xenobiotic that led to the discovery of an enzyme called the soluble epoxide hydrolase (sEH) (Gill et al., 1972; Morisseau and Hammock, 2013). sEH has proved to be key to the biology of a new group of chemical mediators termed the epoxy fatty acids (EpFAs) (Spector and Norris, 2007; Imig, 2012) that regulate surprisingly diverse aspects of biology and show therapeutic utility ranging from inducing anesthesia to combating inflammation and fibrillation (Table 1).

Inhibitors of the sEH are valuable tools in the elucidation of the biological processes regulated by EpFA and have evolved to be potential pharmaceuticals (Shen and Hammock, 2012; Morisseau and Hammock, 2013). Exploiting knowledge on EpFA for therapeutics has required continuing investigation into the metabolism of novel groups of compounds that inhibit the sEH or mimic the EpFA. In this article, a brief review of the history and current state of research on epoxide hydrolases is presented. However, it will focus on the story of a translational project in xenobiotic metabolism that yielded a fundamental insight that was in turn translated into promising therapeutics (Morisseau and Hammock, 2013). In addition, an unexpected fundamental outcome of this work has been a deeper insight into the mechanism of chronic or neuropathic pain leading in turn to a promising therapeutic for this often devastating problem.
While this discussion of the history of epoxide hydrolase discovery is brief, the knowledge on epoxide hydrolase is expansive. There are a number of more comprehensive discussions of epoxide hydrolases in general (Oesch, 1973a; Brooks, 1977; Hammock et al., 1997; Arand et al., 2003; Morisseau and Hammock, 2005; Newman et al., 2005; Decker et al., 2009) and the sEH in particular (Harris and Hammock, 2013; Morisseau and Hammock, 2013). These reviews have been written with emphasis on different facets of sEH, including their enzymatic mechanism (Morisseau and Hammock, 2005; Decker et al., 2009), methods for experimental analysis (Hammock et al., 1985; Wixtrom and Hammock, 1985; Morisseau and Hammock, 2007) and their role in lipid metabolism (Newman et al., 2005; Morisseau, 2013). Likewise, reviews specifically targeting sEH inhibitors (Morisseau and Hammock, 2005; Shen and Hammock, 2012) and enzyme gene structure (Decker et al., 2009; Harris and Hammock, 2013) are available. For more information on the physiologic role of sEH in various disease states, please refer to reviews on their role in cardiovascular disease (Chiamvimonvat et al., 2007; Imig and Hammock, 2009; Imig, 2012), cancer (Norwood et al., 2010; Panigrahy et al., 2011) and pain (Wagner et al., 2011a; Wagner et al., 2011b) and citations in Table 1. Finally, for information on the biology associated with the EpFAs, other reviews have focused on their roles as lipid mediators (Spector et al., 2004; Newman et al., 2005; Spector and Norris, 2007; Spector and Kim, 2014; Zhang et al., 2014a).

A History of Epoxide Hydrolases

The discovery and history of mammalian epoxide hydrolases has been directly linked to the ability to synthesize and characterize the appropriate epoxide substrates. The earliest works on microsomal epoxide hydrolase (mEH or EH1, EC 3.3.2.9) were only possible because of simultaneous work done on metabolites of cyclodiene epoxides by Gerry Brooks (Brooks et al., 1970; Morisseau and Hammock, 2008) and arene epoxides in John Daly’s group (Jerina et al., 1968) (Figure 1) (Table 2). Likewise,
identification of the soluble epoxide hydrolase (sEH or EH2, EC 3.3.2.10) was based on studies by John Casida’s group (Figure 2) characterizing the metabolism of the juvenile hormone mimic, R-20458, which showed novel epoxide hydrolase activity in the soluble fraction of liver homogenates (Gill et al., 1972; Gill et al., 1974) (Figure 3). The mEH and sEH show complementary substrate selectivity and appear to be the major EHs involved in hydrolysis of xenobiotic epoxides while the sEH also appears to be critical for the hydrolysis of the EpFAs. Both the mEH and sEH belong in the superfamily of hydrolases termed α/β-fold hydrolases and share key structural similarities to two other poorly characterized enzymes discussed briefly below, called EH3 and EH4 (Decker et al., 2009). In addition to the epoxide hydrolases linked by genetic similarity, two other mammalian EHs have been identified based on substrate activity. Cholesterol epoxide hydrolase (ChEH) was identified as a unique microsomal epoxide hydrolase that hydrolyzed 5,6-cholesterol epoxide (Oesch et al., 1984; Sevanian and McLeod, 1986; Poirot and Silvente-Poirot, 2013) and leukotriene A₄ hydrolase, not discussed here, was identified based on its selectivity towards leukotriene A₄ (LTA₄) (Maycock et al., 1982; Haeggstrom et al., 2007).

Identification of the Microsomal Epoxide Hydrolase Involved with Xenobiotic Metabolism. The first report of an epoxide hydrolase was published in 1970, when Gerry Brooks was working on the metabolism of insecticides in mammals and insects. At the time, he knew that oxidation of cyclodiene insecticides produced stable and highly toxic epoxides, and it had been demonstrated that hydration of the epoxide of dieldrin could occur in vivo. Jerina et al. (1968) had previously shown that hydration of 1,2-naphthalene oxide occurred in the rat liver microsomes; however, characterization of the enzyme responsible (mEH) had not yet been performed. In his seminal paper, Brooks showed that hydration of the chlorinated cyclodiene epoxides occurred through microsomal enzymes (Brooks et al., 1970). This in turn led Brooks’ development of the hypothesis that inhibiting microsomal EHs could lead to
synergism (Brooks, 1973; Morisseau and Hammock, 2008). Epoxide containing cyclodiene insecticides were first used in his work. However, the rates of hydration were so slow for these insecticides with hindered epoxides that they were of marginal value for characterizing the enzyme. Brooks and team then introduced a less hindered and biodegradable cyclodiene epoxide. This substrate, 1,2,3,4,9,9-hexachloro-6,7-epoxy-1,4,4a,5,6,7,8,8a-octahydro-1,4-methanonaphthalene (HEOM), was hydrolyzed more quickly by the mEH and could be detected by gas-liquid chromatography (GLC), allowing characterization of the microsomal epoxide hydrolase and development of the first inhibitors including the non-competitive inhibitor, 1,1,1-trichloropropane-2,3-epoxide (Brooks, 1973).

While Brooks’ characterized the epoxide hydrolysis in chlorinated insecticides, Daly worked with Jerina and Oesch to determine the metabolism of aromatic hydrocarbons. For Brooks, discovery of the mEH was slowed by the fact that the epoxides he studied were exceptionally stable. In contrast, the work of the NIH group under Daly was hindered by the aromatic epoxides being ephemeral in aqueous environments. During this period, Jerina identified and worked out the mechanism for the “NIH shift”, the intramolecular migration of a hydrogen atom upon hydroxylation (Jerina et al., 1967; Jerina et al., 1968). At the same time, he demonstrated conversion of arene oxides to a series of metabolites including premercapturic derivatives and dihydrodiols (Jerina et al., 1968). Several workers had suggested the formation of dihydroxy metabolites from naphthalene or similar aromatic compounds (Young, 1947; Smith et al., 1950); however, Jerina et al. (1968) were the first to suggest an epoxide intermediate and the enzymatic conversion of epoxides to diols. He would later extend his studies to benzo[a]pyrene, synthesizing all of the potential metabolites to determine which intermediate was the ultimate carcinogen. His work resulted in the identification of diol epoxides as highly mutagenic metabolites (Levin et al., 1976) and the development of the bay region theory, which identified the metabolites that had diol epoxides in the “bay region” of the molecule as those with increased chemical
reactivity resulting in the highest mutagenic potency (Lehr et al., 1985).

While Jerina worked out the mechanism of toxicity for the arene epoxides, Oesch performed the early work on identifying a series of substrates and inhibitors (Oesch et al., 1971b; Oesch, 1973b; Oesch et al., 1973). Just as Brooks’ success relied on developing a rapid GLC-based mEH assay with HEOM, Oesch’s success was largely due to the synthesis of a radiolabeled styrene oxide which turned out to be an excellent substrate for an epoxide hydrolase in the microsomal fraction (Oesch et al., 1971a).

Although this epoxide of styrene was relatively volatile, tended to polymerize, reacted with thiols and was quite unstable at neutral and acidic pHs, it was far easier to use for routine experiments than arene oxides. Oesch took advantage of the difference between the petroleum ether soluble styrene oxide and the water soluble diol product to develop a simple assay for the mEH (Figure 4A) that has since advanced extensive studies on this enzyme (Oesch and Daly, 1971). Unfortunately, the relatively basic pH that was optimum for the microsomal epoxide hydrolase delayed the discovery of epoxide hydrolase activity in the soluble fraction as did inhibition of sEH by styrene oxide.

*Development of juvenile hormone analogs or juvenoids.* The cyclodiene insecticides studied by Brooks proved valuable and were widely used, but many of them were broad spectrum, persistent and toxic environmental contaminants. The publication of *Silent Spring* by Rachel Carson (1962) led to a search for environmentally softer pesticides that avoided the environmental problems of persistent organochlorines and the off-target toxicity of organophosphates. Carroll Williams coined the term 'Third Generation Pesticides' as materials meeting this goal and urged development of mimics of juvenile hormone, the insect terpenoid hormone controlling, among other things, growth and metamorphosis (Williams, 1967) (Figure 3). Like the mammalian EpFAs, these juvenile hormones (Figure 3) were too expensive and unstable to use effectively as insecticides. The epoxide of juvenile
hormone was seen as a liability by some groups, and it was mimicked by a variety of pharmacophores including amides, aziridines, esters, ureas and alkoxides (Henrick et al., 1973; Hammock et al., 1974) in two of the early scaffolds developed. One of these alkoxide mimics from Zoecon Corp (now Wellmark), ZR 515 or methoprene, continues to be a major agent for the control of fleas, mosquitoes and other insects. Another mimic from Stauffer Chemical Company retained the epoxide. It was during the study of this insect growth regulator that the soluble epoxide hydrolase was discovered (Gill et al., 1972; Hammock and Quistad, 1976).

**Discovery of the soluble epoxide hydrolase.** In the early 70s, John Casida assigned two students, Sarjeet Gill and Bruce Hammock, to examine the metabolism of the Stauffer juvenile hormone mimic or juvenoid R-20458. Following its radiosynthesis, the juvenoid was found to be metabolized in insects in part by a microsomal EH that later became known as the juvenile hormone epoxide hydrolase or JHEH. It has since been found that insect juvenile hormones are regulated as much by degradation as by biosynthesis (Hammock, 1985), an observation that was important in later studies on regulation of EpFA in mammals. This and work on the metabolism of the natural insect hormones led to synthesis of many compounds with epoxide mimics. One of these, as previously mentioned, remains as the commercial product termed methoprene (Figure 3). Lessons from these isosteres are now being used to generate mimics of EpFAs.

As one would anticipate, the mammalian oxidative metabolism *in vivo* and *in vitro* of R-20458 led to numerous metabolites generated from combinations of omega hydroxylation, allylic hydroxylation, cyclization and other reactions. However, in liver homogenate preparations lacking NADPH, a single diol metabolite was found in the microsomal and largely in the soluble fraction of liver homogenates (Gill et al., 1972). Since epoxide hydration was thought to be due to one enzyme found in the
microsomal fraction (Oesch and Daly, 1972), it was surprising to find that most of this catalysis was in the 100,000g soluble fraction. In fact, it was later discovered that the small amount of hydrolysis of R-20458 in the microsomal fraction was actually due to traces of the sEH bound to the endoplasmic reticulum (Guenthner et al., 1981). In the end, it was the resistance of R-20458 to glutathione conjugation and high selectivity of sEH for this tri-substituted epoxide that led to the discovery of a new epoxide hydrolase distinct from mEH.

The reasons that sEH was previously overlooked are covered in several papers (Ota and Hammock, 1980; Morisseau and Hammock, 2008). Gill, Hammock and Casida assumed incorrectly that the sEH had been overlooked because it showed such a high preference for trisubstituted epoxides as substrates (Gill et al., 1974; Hammock et al., 1976). This was based in part on careful reading of papers from E.J. Corey's laboratory at Harvard that provided evidence for an enzyme hydrolyzing trisubstituted squalene oxides and related compounds (Dean et al., 1967). Based on this work it could be argued that the Corey laboratory actually first reported the sEH in S-9 preparations, but further observations on the sEH from Harvard ended when the group switched to pure microsomal preparations (Morisseau and Hammock, 2008). It was not until the work of Mumby and Hammock (1979) that it was observed that the sEH actually turns over most mono-substituted epoxides faster than the mEH and seems to prefer cis and trans-1,2-disubstituted epoxides as substrates over tri- and tetra-substituted epoxides. Ota and Hammock (1980) found the discrepancy was not from errors in the early work on the mEH, where the enzyme in rat liver was found with cyclic epoxides and styrene oxide as substrates and a basic pH to be microsomal. Rather the error was with later reviews that extrapolated from the original data on mEH to multiple species, substrates and assay conditions (Oesch and Daly, 1972; Gill and Hammock, 1980; Hammock et al., 1980a; Ota and Hammock, 1980). Early studies used rat liver as a model and the laboratory rat has by far the lowest level of sEH of any mammalian species studied (Gill and
Hammock, 1980; Fornage et al., 2002). The sEH does not hydrolyze epoxides on cyclic systems (Moghaddam et al., 1997), and thus would not have been seen with these substrates. Although the sEH turns over styrene oxide rapidly, it is actually inhibited by the substrate and also would have been overlooked using this tool. Ironically, closely related and more chemically stable substrates such as allyl benzene oxide or trans-β-ethyl-styrene oxide are rapidly metabolized by the sEH (Table 2) (Ota and Hammock, 1980). Since the mEH activity is optimum at basic pH and such a pH is needed to increase stability of styrene oxide, these conditions were commonly used. Inadvertently, these conditions minimize the relative activity of the sEH. Simplistically, both the sEH and mEH have broad and partially overlapping substrate selectivities with the mEH preferring epoxides on cyclic systems and mono-substituted epoxides and the sEH preferring 1,2-disubstituted epoxides.

A Second Mammalian Microsomal Epoxide Hydrolase: ChEH. The biology and chemistry of ChEH has been reviewed previously (Silvente-Poirot and Poirot, 2012; Poirot and Silvente-Poirot, 2013), so the history of ChEH will be described here only briefly. Prior to the identification of a ChEH, 5,6-cholesterol epoxide had been shown to be enzymatically converted to cholestanetriol by several groups (Black and Lenger, 1979; Sevanian et al., 1980; Watabe et al., 1980). The enzyme responsible for 5,6-cholesterol epoxide hydrolysis was eventually identified as a microsomal epoxide hydrolase that was determined to be distinct from mEH based on antigenicity (Oesch et al., 1984) and inhibitor selectivity (Sevanian and McLeod, 1986). Despite many studies characterizing enzymatic activity and tissue distribution (Astrom et al., 1986) of ChEH, only recently has the molecular entity been characterized. Surprisingly, the molecular entity responsible for the ChEH activity was in fact the antiestrogen binding site (AEBS), a multidomain protein that has high-affinity for the pharmaceutical tamoxifen, which is composed of two enzymes, 3β-hydroxysterol-Δ7-Δ8-isomerase (D8D7I) and 3β-hydroxysterol-Δ7-reductase (DHCR7), involved in cholesterol synthesis (de Medina et al., 2010). The
Kᵢ for tamoxifen inhibition of ChEH is 34 nM. Since effective doses of tamoxifen are low micromolar, cholesterol epoxides potentially contribute to the biological activity of tamoxifen.

For years, it had been believed that 5,6-cholesterol epoxides had a role in carcinogenesis (Petrakis, 1986; Poirot and Silvente-Poirot, 2013). Although early studies indicated 5,6-cholesterol epoxide binds covalently to nucleophilic DNA (Blackburn et al., 1979; Sevanian and Peterson, 1984), 5,6-cholesterol epoxide is relatively unreactive with nucleophiles, only forming adducts with mercaptoethanol and aminoethanol under catalytic conditions (Paillasse et al., 2012). Despite this lack of chemical reactivity, an undescribed enzyme was found to catalyze the addition of histamine to 5,6α-cholesterol epoxide, resulting in Dendrogenin A (DDA). This compound is a potent tumor suppressor that induces cell differentiation and is also a potent, selective inhibitor of ChEH (de Medina et al., 2009; de Medina et al., 2013). DDA has been found in mammalian tissue with levels significantly reduced in breast cancer tissues. It was shown to significantly enhance survival time of mice implanted with tumors (de Medina et al., 2013). Given that non-diol downstream metabolites of 5,6α-cholesterol epoxide have been implicated in enhanced tumor survival, it has been suggested that tamoxifen and DDA could both reduce cancer severity through a common mechanism of ChEH inhibition (de Medina et al., 2013). Targeting ChEH may therefore represent a new therapeutic approach with similar efficacy to tamoxifen but with reduced off-target effects.

**Epoxy fatty acids are chemical mediators and endogenous substrates of sEH**

Based on the distribution and properties of sEH, Gill and Hammock correctly hypothesized that it had an endogenous role in regulating chemical mediators. Early on they thought that it might be a scavenger enzyme that hydrolyzed terpene epoxides such as squalene dioxide and lanosterol epoxide.
Involvement of sEH in these reactions has never been ruled out, but the discovery by Mumby and Hammock (1979) that 1,2-disubstituted epoxides were turned over far faster than tri- and tetra-substituted epoxides led to the hypothesis that fatty acid oxides were endogenous substrates, which was quickly confirmed by Gill and Hammock (1979). Furthermore, Chacos et al. (1983) demonstrated the epoxyeicosatrienoic acids (EETs), epoxides of arachidonic acid, were substrates as well. Later work would identify epoxides of lineolate, termed leukotoxins, as substrates that become bioactivated to inflammatory diols by the sEH (Moghaddam et al., 1997).

Although sEH inhibition is primarily discussed in the context of biologically active EpFAs, the leukotoxin-diols remain important toxic mediators for acute respiratory distress syndrome (ARDS) and possibly endogenous mediators regulating vascular permeability and inflammation (Zheng et al., 2001).

There were hints of biological roles for EpFAs in the literature for years but technical issues, including the wide abundance of the sEH in tissues, rapid metabolism of EpFAs by sEH, the general lack of availability of these epoxides and dearth of good analytical methods, slowed the field. However, critical breakthroughs towards understanding the biological role of EpFAs were made after the development of sEH inhibitors. There were multiple attempts to develop potent inhibitors of the sEH as well as the mEH, with most inhibitors being either alternate substrates or substrates that were slowly turned over (Morisseau and Hammock, 2005). However, the discovery that carbamates, amides and ureas as linear and heterocyclic systems are competitive transition state inhibitors of the enzyme led to compounds that were generally useful for demonstrating the biological effects of EpFAs in vivo (Morisseau et al., 1999; Kim et al., 2004; Kim et al., 2005). These inhibitors, combined with the later development of knock out animals, has fostered multiple discoveries regarding the diverse biological actions of EpFAs and led to the general appreciation that there is a third cytochrome P450 branch of the arachidonic acid cascade.
Development of transition state competitive inhibitors of the sEH

Early non-competitive inhibitors of the sEH were too unstable for effective use in vivo (Mullin and Hammock, 1982). The first potent competitive inhibitors of the sEH included materials like the industrial by-product dicyclohexyl urea (DCU, Figure 5) and a variety of diphenyl ureas (Morisseau et al., 1999). Although quite potent, these and related compounds like 1-cyclohexyl-3-dodecyl urea (CDU) were difficult to use in vivo and, as expected of lipophilic high-melting solids, difficult to formulate. However, the availability of inhibitors allowed for crystal structures demonstrating hydrogen bonding between urea inhibitors and the enzyme active site residues (Argiriadi et al., 2000), confirming previous kinetic evidence demonstrating competitive inhibition determined using the high-affinity model substrate trans-diphenylpropene oxide (t-DPPO) (Morisseau et al., 1999). In a latter study, Morisseau et al. (2010) determined the $V_m$, $K_m$ and $k_{cat}$ of several EpFA and found that, like t-DPPO, they have a high specificity ratio ($V_m/K_m$). This work indicates high target occupancy of an inhibitor will be critical for effective inhibition of the enzyme in vivo. An advance was made when 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA) was prepared as a mimic of the 14,15-epoxide of arachidonic acid. Within the molecule, a dodecanoic acid was used to mimic the alpha end of arachidonic acid, a 1,3-urea was used to mimic the epoxide and its transition state, and an adamantane was used to mimic the omega hydrophobic tail (Morisseau et al., 2002). The adamantane was a fortunate selection, since it provided high sensitivity for detection on LC-MS, so that only a few microliters of blood were required to follow in vivo levels and thus allowed for optimization of future structures for PK-ADME (Watanabe et al., 2006). AUDA remains among the most potent sEH inhibitors with significantly greater potency than the IND candidate AR9281 described below. However, its physical properties and rapid metabolism make it challenging to use. Additionally, its
activity as a moderate PPAR alpha agonist (Fang et al., 2005) and as a reasonably potent mimic of EETs (Olearczyk et al., 2006) has made it experimentally unfavorable.

Subsequent work in this and other series of compounds has led to compounds of improved physical properties but also improved potency and PK-ADME (Morisseau and Hammock, 2013). Generally, most of these compounds retain the urea pharmacophore; however, several contain carbamate or amide groups that form strong transition state interactions with the enzyme active site. Given similarities in the sEH active site and the active sites of other $\alpha/\beta$-fold enzymes, it seems plausible that other $\alpha/\beta$-fold hydrolase inhibitors, including inhibitors of fatty acid amide hydrolase (FAAH), may inhibit sEH.

Although physical properties have improved slightly, many of the inhibitors have high melting points and low water solubilities. Generally, increasing water solubility and decreasing the melting point of sEH inhibitors are important goals. However, it is relatively easy to formulate water soluble materials regardless of melting point and even with increasing lipophilicity, formulation remains relatively easy as long as the melting point is low or the potency is high. However, for these high melting point lipophilic compounds, effective biological experiments have relied on careful formulation. Fortunately, as one improves potency and PK-ADME, the required dose drops and formulation is simplified (Shen and Hammock, 2012). The development of high throughput techniques for testing potency has been necessary for SAR experiments in order to optimize potency, solubility and melting point. The availability of recombinant enzymes and a high-turnover fluorescent-based substrate (Cyano(6-methoxy-naphthalen-2-yl)methyl trans-[(3-phenyloxiran-2-yl)methyl] carbonate, CMNPO) synthesized by Jones et al. (2005) has allowed for the development of rapid assays for testing inhibitor potency (Figure 4B). More recently, inhibitors have also been tested using a fluorescent probe (1-(adamantan-1-yl)-3-(1-(2-(7-hydroxy-2-oxo-2H-chromen-4-yl)acetyl)piperidin-4-yl)urea, ACPU) that engages in Förster Resonance Energy Transfer (FRET) with neighboring tryptophan residues in the sEH active site.
DMD # 63339

(Figure 4C). This tool decreases the lower limit for determining potency and can be used for measuring \( k_{\text{off}} \), the rate at which inhibitors leave the active site (Lee et al., 2013; Lee et al., 2014). High enzyme target occupancy, as determined by \( k_{\text{off}} \), appears particularly important in predicting the *in vivo* efficacy of sEH inhibitors. This is because the inhibitors are competing with low abundance, but biologically powerful substrates with high affinity for the enzyme (Morisseau et al., 1999; Schebb et al., 2011).

Along with increased potency, the PK has shifted from highly aliphatic and quickly metabolized inhibitors to compounds with long half-lives in a variety of species including dogs and non-human primates (Tsai et al., 2010; Ulu et al., 2012). Inhibitors have also evolved for multi-target engagement towards cyclooxygenase (COX) (Hwang et al., 2011) and lipoxygenase (Meirer et al., 2013). Dual sEH/COX inhibition results in synergism that dramatically improves the potency of compounds (Zhang et al., 2014b). In the process of optimizing the medicinal chemistry, a number of these compounds have been evaluated as clinical candidates (Figure 6).

**Discovering physiologic roles for epoxy fatty acids**

Although the role of sEH in epoxy fatty acid hydrolysis was discovered relatively early, it has not been until the past 15 years that a physiologic role for this enzyme has been generally realized. Epoxyeicosatrienoic acid (EET) generated by oxidation of arachidonic acid had previously been shown to regulate vasodilation (Carroll et al., 1987) and Ca\(^{2+}\) uptake (Kutsy et al., 1983). Although other metabolic pathways have been described including \( \beta \)-oxidation, chain elongation and glutathione conjugation, the contribution of these pathways is minor except when sEH is inhibited. For example, the specific activity for glutathione S transferase on enzymatic conjugation of EET is approximately 100-fold less than hydration of EET by sEH. (Spearman et al., 1985; Morisseau et al., 2010). Thus, in tissues where expression of these two enzymes is comparable, glutathione conjugates are significantly
less abundant than diol metabolites. Yu et al. (2000) were the first to show that inhibition of sEH could regulate a biological process by demonstrating that sEH inhibitors caused a marked reduction in hypertension. Since then, sEH inhibition has been investigated in numerous disease states in multiple organ systems (Table 1). Generally, a few physiologic mechanisms, including resolution of inflammation, vasodilation and enhanced tissue repair, account for most of the biological activities observed; however, there are several exceptions. Increasingly, reduction of and resistance to reactive oxygen species (ROS)-induced endoplasmic reticular (ER) stress appears to be an underlying mechanism (Bettaieb et al., 2013).

Several of the effects seen with EETs have been observed with the epoxide derivatives of ω-3 fatty acids, including epoxyeicosatetraenoic acid (EpETE), an epoxide of eicosapentaenoic acid (EPA), and epoxydocosapentaenoic acid (EpDPE), an epoxide of docosahexaenoic acid (DHA) (Morisseau et al., 2010; Ulu et al., 2014). In the case of angiotensin II (AngII) induced hypertension, the connection between an increase in EpDPEs caused by dietary ω-3 fatty acid consumption and sEH inhibitor treatment has been clearly demonstrated. When directly comparing the effects of the EpDPEs against EETs with co-administration of the sEH inhibitor, EpDPEs are more efficacious at reducing AngII induced hypertension (Figure 7B). If the amount of EpDPEs generated relative to EETs is modified by increased ω-3 fatty acids in the diet, the effects of the sEH inhibitor are improved. By co-administering the ω-3 fatty acid diet with sEH inhibitors, the dose of sEH inhibitors needed may be reduced (Figure 7A). However, this also emphasizes the need for understanding diet-drug interactions to reduce unwanted side effects.

One of the most interesting and exciting, but still poorly understood therapeutic applications for sEH inhibitors is the regulation of pain. Early on, it was found that inhibition of sEH could prevent acute
inflammation (Schmelzer et al., 2005). As expected, the reduction in inflammation through sEH inhibition led to analgesia from inflammatory pain (Inceoglu et al., 2006). Reduced inflammatory pain is observed even when pain is induced by prostaglandin E2 (PGE2), indicating anti-inflammation occurs downstream or independently of cyclooxygenase signaling (Figure 8A) (Inceoglu et al., 2011). Unexpectedly, other forms of pain that are not inflammation-based, such as traumatic nerve injury or diabetic neuropathic pain, have also been prevented by sEH inhibition (Inceoglu et al., 2012).

Neuropathic pain has been traditionally difficult to treat due to low efficacy of non-steroidal anti-inflammatory drugs (NSAIDs) and undesirable side effects of other therapies including morphine and gabapentin (Inceoglu et al., 2012). Since there are only three FDA approved therapeutics for neuropathic pain and no therapy fully treats neuropathic pain, development of a sEH inhibitor for neuropathic pain would serve an unmet medical need. Many NSAIDs, including diclofenac, sometimes can enhance neuropathic pain. Interestingly, the sEH inhibitors synergize with diclofenac to reduce pain in a streptazocin-induced model of diabetic neuropathy, indicating dual COX/sEH inhibition may prove to be an effective strategy for reducing neuropathic pain while keeping side effects low (Figure 8B) (Hammock et al., 2011). In addition to NSAIDs, the sEH inhibitors synergize with phosphodiesterase (PDE) inhibitors (Inceoglu et al., 2011), which may be an alternative approach towards improving potency. The efficacy of EETs in the presence of increased cAMP, in part, explains the analgesic efficacy of sEH inhibitors in the presence but not the absence of pain. The mechanism by which sEH inhibitors reduce neuropathic pain are still being investigated; however, components of cannabinoid (Wagner et al., 2011b), opioid (Terashvili et al., 2008; Conroy et al., 2010) and neurosteroid signaling (Wang et al., 2006; Inceoglu et al., 2008) have been implicated in the pain-relieving effects of EETs and other EpFA.

Aside from analgesic properties, the epoxidized fatty acids also regulate angiogenesis and metastasis.
Unlike inflammation and analgesia, where the effects of ω-3 and ω-6 metabolites are similar, the ω-3 metabolites inhibit VEGF-mediated angiogenesis and metastasis (Zhang et al., 2013) whereas the ω-6 metabolites promote angiogenesis and metastasis (Panigrahy et al., 2012). Compounds that reduce angiogenesis have previously been investigated therapeutically to prevent cancer recurrence. On the other hand, angiogenesis is essential for organ growth and tissue regeneration and its promotion could be used to improve wound healing. Therefore, modulation of these metabolites by sEH inhibition could be therapeutically beneficial for both inhibiting cancer recurrence and for promoting wound healing, but likely such therapeutic approaches will require careful regulation of ω-3 and ω-6 metabolites through dietary intervention.

Other physiological effects of the EpFAs that could lead to therapeutic uses have been identified in the past several years; however, further research is needed to fully understand their mechanisms and overall benefit. Inhibition of sEH attenuates the normal ER stress response, which could have implications for metabolic disorders (Bettaieb et al., 2013). Additionally, the ER stress response has been linked to a number of neurodegenerative disorders but no studies have investigated sEH inhibition on these endpoints.

Developing a Path to the Clinic

There are many possible therapeutic uses of sEH inhibitors, EpFAs, and their mimics ranging from quite obvious indications such as hypertension and pain to more obscure uses. Potential clinical trials for uses such as cardiac ischemia or atrial fibrillation appear relatively straightforward, while clinical trials for stroke, artherosclerosis or sepsis would be more difficult. Numerous factors go into decisions regarding a clinical path for development, as discussed in the context of sEH inhibitors by Shen and
Hammock (2012). These decisions go beyond chemical properties of the molecule and target efficacy to include such things as budgetary constraints, developer expertise, and the patent landscape.

A recently explored clinical application for sEH inhibitors as therapeutics has been the reduction in inflammatory and neuropathic pain. They are as effective in animal models of inflammatory disease as NSAIDs and COXIBs (Schmelzer et al., 2006; Wagner et al., 2011b) and reduce the gastrointestinal erosion and cardiovascular effects associated with the use of cyclooxygenase inhibitors. However, the clinical trials required for using sEH inhibitors to treat inflammatory pain are long and the current therapies are sufficiently effective if doses are monitored carefully, making a pathway to the clinic difficult in humans. On the other hand, neuropathic or chronic pain remains an unmet medical need and sEH inhibitors have proven efficacious in rodent models and equine laminitis patients (Guedes et al., 2013). sEH inhibitors are particularly attractive because they are non-opiate and non-NSAID compounds which do not impair cognition, mobility or coordination in animal trials. In the chronic pain field, it is notoriously difficult to extrapolate from rodent models to man, but this difficulty potentially arises as much from using disease models rather than patients as it does from differences between chronic pain in man and other animals. Most rodent studies involve pain reduction in mouse or rat experimental models of pain. In contrast, treating patients for clinical pain often requires addressing other complex disease factors not considered in a rodent model. EicOsis Animal Health has already begun trials to treat inflammatory and neuropathic pain in companion animals, a market which primarily consists of dogs and cats. Its sister company, EicOsis Human Health is working on chronic pain in man. A third company, Sphaera, has also run a successful human clinical trial using a topical application of a sEH inhibitor to treat diabetic peripheral neuropathy. Thus, some confidence in ultimate clinical success with sEH inhibitors to treat pain comes from pain reduction in 5 different animal orders. In addition to pain, several studies suggest that sEH inhibitors could be broadly effective
in a variety of diseases involving neuro inflammation (Hung et al., 2014).

Other clinical applications, including reduction in hypertension, myocardial infarction and diabetes, have been covered previously in (Shen and Hammock, 2012) but are worth discussing briefly. The first biological application where efficacy was determined in vivo and the first clinical target by Arête Therapeutics was reduction in hypertension. The sEH inhibitors were clearly active, resulting in decreased blood pressure in AngII-induced rodent models (Jung et al., 2005) and a dramatic reduction in hypertension for horses with severe laminitis (Guedes et al., 2013). Unfortunately, Arête Therapeutics was unsuccessful at developing AR9281 (Figure 6), an IND candidate, into a marketed drug largely due to mediocre efficacy and short half-life. sEH inhibitors have also been investigated for the improvement of cardiac function and reduction of cardiac fibrosis after myocardial infarction in a mouse model (Sirish et al., 2013). Trials for cardiac hypertrophy caused by fibrosis are notoriously expensive and long; however, there is a serious need for drugs that will attenuate hypertrophy. Additionally, numerous co-morbidities associated with diabetes are effectively controlled in animal models by sEH inhibitors, but the effectiveness on diabetes itself has varied with the animal model evaluated (Luria et al., 2011; Chen et al., 2013). ER stress, a component of many disease states including diabetes, appears to be significantly reduced by giving sEH inhibitors and represent an additional approach towards getting to the market (Bettaieb et al., 2013). In fact, in mice with enhanced levels of ω-3 fatty acids, sEH inhibitors reduce the symptoms of diabetes (López-Vicario et al., 2015).

The profile of EpFA associated with sepsis suggests that sEH inhibitors should also be very effective at treating sepsis related mortality (Zheng et al., 2001; Schmelzer et al., 2005; Liu et al., 2009). Particularly, the high level of plasma linoleate diol or leukotoxin suggests a role for sEH in therapy.
A variety of studies using rodent models have shown that many of the symptoms associated with sepsis can be blocked by sEH inhibitors resulting in reduced mortality. One of the most dramatic effects of sEH inhibitors in sepsis has been in reducing morbid hypotension (Liu et al., 2009). Since clinical treatment of hypotension is exceptionally difficult, the sEH inhibitors would offer an attractive new approach. However, predicting which patients will develop acute respiratory distress syndrome (ARDS), multi-organ failure or sepsis will make execution of a clinical trial difficult. Compassionate use treatments for serious viral infections, such as those associated with swine flu or Ebola, could potentially provide a clinical path for using sEH inhibitors to reduce sepsis. The Arête Therapeutics IND candidate, AR9281, for example, represents a new approach with an IND on file with the FDA that could be evaluated for sepsis.

Finally, a promising candidate produced by GlaxoSmithKlein, GSK2256294, has gone through phase I trials, two phase II trials are underway for the treatment of chronic obstructive pulmonary disorder (COPD) and a vascular trial has been announced (GlaxoSmithKline, 2014). COPD is common among chronic smokers and was estimated to affect 5.1% of the population in 2009 (Akinbami and Liu, 2011), making it a good indication for potential entry into the market for sEH inhibitors. GSK2256294 demonstrates pM activity towards sEH, effectively increases in vivo EET/DHET and EpOME/DiHOME ratios and reduces cell counts of macrophages, neutrophils and keratinocyte chemoattractant (KC) cells of smoke exposed rodents (Podolin et al., 2013). These observations are consistent with several studies demonstrating the efficacy of sEH inhibitors at reducing inflammation and general lung injury from smoke exposure (Smith et al., 2005; Wang et al., 2012) and asthma (Yang et al., 2015).

Future Challenges in Epoxide Hydrolases
Thus far, discovery in the field of epoxide hydrolases has led to insight on the roles of important lipid mediators called EpFAs as well as development of potential pharmaceuticals based on potent inhibition of sEH with optimized PK-ADME. Yet, there are hints that opportunity is still available for novel discoveries in the EH field.

Each monomer of the sEH anti-parallel homodimer consists of two globular proteins linked by a proline rich bridge. The role of the N-terminal phosphatase domain, first characterized a decade ago, remains poorly understood. The phosphatase activity was identified and characterized using the artificial substrates 4-nitrophenyl phosphate and 4-methylumbelliferyl phosphate (Cronin et al., 2003) and a number of dihydroxy lipid phosphates (Newman et al., 2003). Unfortunately, these early lipid phosphates were not detected in biological samples. Recently, lysophosphatidic acids have been identified as substrates for the phosphatase domain of sEH, with activity higher than the lipid phosphate phosphatases believed to be responsible for their hydrolysis (Oguro and Imaoka, 2012; Morisseau et al., 2013). There is additional evidence that the phosphatase domain regulates cholesterol levels (EnayetAllah et al., 2008) and eNOS activity (Hou et al., 2012); however it is unclear what the exact substrates are for the phosphatase domain. The simultaneous inhibition of both the epoxide hydrolase and phosphatase activities of sEH by the thrombolysis drug SMTP-7 suggests a possible clinical role for dual inhibitors (Matsumoto et al., 2014). In nematodes, homologs of the phosphatase domain are separate enzymes (Harris et al., 2008) as they are in plants. However, the conservation of the phosphatase as well as the epoxide hydrolase protein from the prokaryotic through eukaryotic species suggests fundamental biological roles.

Recently, a number of epoxide hydrolases whose activity has not been linked to physiologic relevance
or a mediating substrate have been described. Two of these, the EH3 and EH4, were identified as theoretical epoxide hydrolases by comparing structural homology to mEH and sEH. So far only EH3 has been successfully expressed recombinantly and neither protein has a demonstrated role in vivo (Decker et al., 2012). EH3 has been reported to hydrolyze EpFAs (Decker et al., 2012), but there is no indication that this activity is related to its endogenous function. In addition to the EH3 and EH4, CFTR inhibitory factor (cif) is a virulence factor with epoxide hydrolase activity produced by the bacterium Pseudomonas aeruginosa that contributes to the progression of cystic fibrosis. It has been reported to hydrolyze the sEH substrate CSO (Bahl et al., 2010), but it has not been reported to hydrolyze a natural substrate and the connection between EH activity and disease progression is poorly understood. Certainly, EHs are widespread in prokaryotic and eukaryotic species with physiological roles yet to be determined. Aside from these novel EHs, there is the possibility that the microsomal epoxide hydrolase, typically studied in the context of xenobiotic metabolism, has a role in endogenous epoxide metabolism. Many papers have minimized the contributions of mEH on EET metabolism due to the low activity relative to sEH and relatively low abundance, but the contribution of mEH towards hydrolysis of EETs and other EpFA may be significant in cell types with low sEH abundance including some neurons (Marowsky et al., 2009). Similar to how the identification of juvenile hormones and EpFAs was important towards understanding the role of JHEH and sEH, the essential step towards understanding the physiologic role of mEH and these novel EHs will be the identification of the novel epoxides or diols that act as chemical mediators.

In addition to the epoxide hydrolases discussed here in mammals and insects, there have been epoxide hydrolases identified in a range of organisms, including plants (Newman et al., 2005), bacteria (Arand et al., 2003), the nematode C. elegans (Harris et al., 2008) and other animals including chickens (Harris et al., 2006) and amphibian Xenopus (Purba et al., 2014). To accommodate new discoveries in the EH
field, it will be necessary to adopt a naming system similar to that generated for the cytochrome P450 (CYP450) superfamily (Nebert et al., 1987; Nelson, 2004), which currently has at least 20,000 members representing both prokaryotic and eukaryotic organisms (Nelson, 2009). For CYP450s, identified CYP450s are divided into numerical families based on 40% sequence identity and can be further organized into alphabetical sub-families if enzymes maintain at least 55% sequence identity. Successful implementation of an EH nomenclature would allow systematic comparisons of EH substrate selectivity, activity and physiological relevance across species. As more EH enzymes are described, the importance of such a systematic nomenclature system will increase.

Conclusion

It appears that most xenobiotic epoxides are hydrolyzed by either the mEH or sEH, the former enzyme being responsible for epoxides on most cyclic systems. An investigation into the mammalian metabolism of an early insect growth regulator led to the discovery of the soluble epoxide hydrolase which degrades some xenobiotics but is largely responsible for the hydration of EpFAs. Many of these EpFAs are potent chemical mediators formed in the cytochrome P450 branch of the arachidonate cascade. EpFA generally can be considered as having the opposite effects of mediators from the better studied cyclooxygenase and lipoxygenase branches of the cascade which are largely but not exclusively hypertensive, pro-inflammatory, and pain inducing mediators.

A variety of authors demonstrated that in insects the hydrolysis of the terpenoid insect juvenile hormone by α/β-fold esterases and epoxide hydrolases is as important in regulating its biology as is the biosynthesis of the hormone (Hammock and Quistad, 1976). Similarly, with EpFA such as EETs and EpDPEs, the regulation of the titer of these chemical mediators by degradation seems as important as
biosynthesis. Spector and co-workers (Fang et al., 2004) showed that the soluble epoxide hydrolase is the major enzyme involved in the degradation of EETs, and its inhibition increases the plasma and presumably tissue levels of a variety of these generally beneficial EpFA chemical mediators.

Thus, an applied study of the metabolism of a xenobiotic for use in agriculture and vector control led to the discovery of the soluble epoxide hydrolase. Addressing fundamental questions regarding the enzyme's biochemistry, catalytic mechanism and physiology led to potent inhibitors which, as physiological probes, demonstrated endogenous roles for the natural EpFA chemical mediators. These same inhibitors now appear promising for the control of a variety of illnesses in man and in companion animals. This is particularly true for the largely unmet medical need of neuropathic pain and a variety of acute pain indications. The sEH inhibitors as well as the EpFA and their mimics offer the possibility of non-NSAID, non-opiate therapeutics for inflammatory and neuropathic pain. To date, the principle value of sEH inhibitors has been in demonstrating endogenous roles for the EpFA chemical mediators and in determining their mechanism of action. In doing so, the sEH inhibitors illustrate a possible therapeutic role for mimics of EpFA just as the chemical mimics of insect juvenile hormone have proven to be valuable tools in the control of disease vectors and agricultural pests. The EH field as have several others, illustrate that the study of xenobiotic metabolism is an essential component of translational science in drug development. However, it also offers new biological insight which is, in this case, being translated into novel therapeutics.

Acknowledgements: The authors would like to thank Arzu Ulu, Karen Wagner, Bora Inceoglu, Todd Harris and Christophe Morisseau for their helpful comments in the preparation of this manuscript.

Authorship Contributions: Wrote or contributed to the writing of the manuscript: S.D. Kodani and B.D. Hammock
References


DMD # 63339

89:3347-3349.


Morisseau C, Inceoglu B, Schmelzer K, Tsai HJ, Jinks SL, Hegedus CM, and Hammock BD (2010) Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are...


DMD # 63339

Footnotes:

This work was funded by the National Institutes of Health National Institute of Environmental Health Sciences [Grant ES002170, ES004699]; National Institutes of Health National Institute of Neurological Disorders and Stroke [Grant AR062866]; and the Research Investments in the Science and Engineering (RISE) Program at the University of California, Davis.

Competing financial interests declaration: B.D.H. is a co-founder of EicOsis LLC and has several patents on soluble epoxide hydrolase technology.
DMD # 63339

**Figure Legend**

**Figure 1. Pioneers in the Discovery of Microsomal Epoxide Hydrolase.** Gerry Brooks (top left) studied the metabolism of cyclodiene insecticides, resulting in the first publication characterizing an epoxide hydrolase found in microsomes. Franz Oesch (bottom left) and Donald Jerina (bottom right), both led by John Daly (top right), studied the metabolism of aromatic hydrocarbons leading to detailed characterization of the mEH.

**Figure 2. Early Discovery of the Soluble Epoxide Hydrolase.** Under the guidance of John Casida (right), Sarjeet Gill (left) and Bruce Hammock found a novel epoxide hydrolase in the soluble fraction of liver homogenate that hydrolyzed R-20458.

**Figure 3. Juvenoid hormone (JHI) and juvenile hormone mimics methoprene and R-20458.** A study of the insect hormone led to commercial hormone juvenile mimics like methoprene and to the discovery of the soluble epoxide hydrolase during the study of the JH mimic R-20458.

**Figure 4. Methods for measuring EH activity.** Several substrates have been generated for rapid analysis of EH enzymes and more sophisticated kinetic treatments. **A.** The radioactive [7-^3^H] styrene oxide developed by Oesch et al (1971a) used water solubility of the diol to monitor the reaction kinetics and a similar partition method was used for trans-β-ethyl styrene oxide (see Table 2) (Mullin and Hammock, 1980), trans-stilbene oxide (see Table 2) (Gill et al., 1983) and t-DPPO (Borhan et al., 1995). **B.** More recent substrates rely on cyclization of the epoxide hydration product to release a chromophore. In the case of CMNPO, the pro-chromophore is a nonfluorescent cyanohydrin which spontaneously hydrolyzes to yield CN^−, for which there are sensitive reagents, and an intensely fluorescent, red shifted methoxynaphthaldehyde (Jones et al., 2005). **C.** There are a variety of techniques for high throughput analysis of binding of a fluorescent molecule, such as ACPU designed for the sEH. In this case it was used to determine a K_i value for the enzyme and a kinetic off rate to give an estimation of substrate occupancy of the catalytic site (Lee et al., 2013).
Figure 5. Evolution of sEH inhibitors. Over the past decade, sEH inhibitors have evolved with increased potency, increased PK-ADME and multiple target engagement. From this development, AUDA has been investigated in human clinical trials by GSK and second generation inhibitors have been optimized to IND candidates.

Figure 6. IND and development candidates among sEH inhibitors. GSK2256294 is a potent inhibitor that has demonstrated efficacy \textit{in vivo} and is moving into the clinic (Podolin et al., 2013). Triclocarban (TCC) is a commonly used anti-microbial that also inhibits the human sEH (Schebb et al., 2011) and has proved successful as a topical analgesic when used with diclofenac in a double blind clinical trial for diabetic neuropathic pain. AR9281 (UC1153, APAU), originally reported by Jones et al. (2006), was taken through Phase 2A for hypertension and metabolic syndrome (Anandan et al., 2011). AR9281 is more potent on the rat recombinant sEH than the human, has poor target occupancy of the human sEH and has a short half-life due to rapid P450 metabolism of the adamantane moiety. TPPU or UC1770 shows high potency in rodent and primate species and has been provided to many laboratories as a model sEH inhibitor (Ulu et al., 2012). \textit{t-}TUCB or UC1728 is in trials for the neuropathic pain of equine laminitis (Guedes et al., 2013) and is being evaluated for canine arthritis and feline joint pain.

Figure 7. Efficacy of sEH inhibitors may be improved by supplementing \(\omega\)-3 fatty acids in the diet by producing EpDPEs. A. Either sEH inhibitors or an \(\omega\)-3 rich diet alone partially reduce increase in blood pressure 7 days after angiotensin II injection, while giving both simultaneously reduces blood pressure close to control levels. Data are replotted from Ulu et al. (2013). B. EpDPEs are likely the metabolites responsible for the improved efficacy of simultaneous administration of the \(\omega\)-3 diet and sEH inhibitors. Slow release of EpDPEs into the blood stream achieved by surgical implantation of osmotic mini-pumps resulted in decreased blood pressure 6 days after angiotensin II injection and increasing half-life of EpDPEs by inhibiting sEH increased efficacy. In comparison, EETs with sEH
inhibitors were not as potent towards reducing blood pressure. Data are replotted from Ulu et al. (2014). C. In a rat model of streptozocin-induced diabetic neuropathy, an ω-3 rich diet had minimal effect at increasing pain thresholds relative to those on an oleic oil based diet. However, when administering sub-therapeutic levels (0.3 mg/kg) of sEH inhibitors, rats fed ω-3 rich food had an increased threshold relative to those on a control diet. Data are replotted from Wagner et al. (2014a). D. As seen in hypertension, EpDPEs are likely responsible for the improved efficacy when both an ω-3 diet and sEH inhibitors are used to treat diabetic neuropathy. EpDPEs administered by intraperitoneal injection (1 mg/kg) in a mouse model of diabetic neuropathy were more efficacious at reducing pain than EETs and had a response similar to the sEH inhibitor t-TUCB (10 mg/kg). Data are replotted from Wagner et al. (2014a).

**Figure 8. sEH inhibitors reduce pain downstream of cyclooxygenase (COX) metabolism and can synergize with COX inhibitors.** A. Withdrawal threshold was measured 45 minutes after PGE2 was injected subcutaneously with TUPS, celecoxib (COX-2 inhibitor) or dexamethasone (corticosteroid). Celecoxib and dexamethasone act upstream of PGE2 formation and therefore do not prevent PGE2 induced pain. However, sEH inhibitors do inhibit PGE2 induced pain, indicating they act downstream of PGE2 formation. Data are replotted from Inceoglu et al. (2011) B. sEH inhibitors synergize with diclofenac, a COX inhibitor, to reduce neuropathic pain in a streptazocin-induced model of diabetic neuropathy. Increased EETs are associated with a reduction in blood clotting caused by COX-2 selective inhibitors such as rofecoxib and the gastric erosion from COX-1 inhibitors. Data are replotted from Hammock et al. (2011).
Table 1. Physiologic Roles for EpFAs and sEH. Roles for EpFAs and sEH have been studied in a number of disease states through the use of sEH inhibitors. References are not exhaustive, but are intended to represent original discovery, reviews or most current literature.

<table>
<thead>
<tr>
<th>Organ System</th>
<th>Physiological Consequence</th>
<th>Relevant Disease State</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Circulatory System</td>
<td>Blood Pressure Regulation</td>
<td>Hypertension</td>
<td>Yu et al., 2000; Imig, 2012; Ulu et al., 2014</td>
</tr>
<tr>
<td></td>
<td>Angiogenesis</td>
<td>Cancer, Wound Healing</td>
<td>Panigraphy et al. 2012; Zhang et al., 2013</td>
</tr>
<tr>
<td></td>
<td>Reduced Protein Aggregation</td>
<td>Heart Failure</td>
<td>Despa et al., 2014</td>
</tr>
<tr>
<td></td>
<td>Reduced Fibrosis</td>
<td>Cardiac Hypertrophy</td>
<td>Sirish et al., 2013; Li et al., 2014</td>
</tr>
<tr>
<td>Peripheral Nervous System</td>
<td>Reduced Inflammatory Pain</td>
<td>Acute Pain</td>
<td>Inceoglu et al., 2006; Schmelzer et al. 2006; Wagner et al., 2011a</td>
</tr>
<tr>
<td></td>
<td>Reduced Neuropathic Pain</td>
<td>Chronic pain</td>
<td>Inceoglu et al., 2008; Wagner et al., 2011b; Guedes et al., 2013; Wagner et al., 2014b</td>
</tr>
<tr>
<td>Respiratory System</td>
<td>Bronchodilation</td>
<td>Asthma</td>
<td>Lundstrom et al., 2011; Lundstrom et al. 2012</td>
</tr>
<tr>
<td></td>
<td>Pulmonary Vascular Shunting</td>
<td></td>
<td>Smith et al., 2005; Wang et al., 2012</td>
</tr>
<tr>
<td>Kidney</td>
<td>Reduced Fibrosis</td>
<td>Kidney Failure</td>
<td>Kim et al., 2014</td>
</tr>
<tr>
<td></td>
<td>Renal Vascular Function</td>
<td>Kidney Failure</td>
<td>Zhao et al., 2004; Imig, 2012; Kujal et al. 2014</td>
</tr>
<tr>
<td>Liver</td>
<td>Tissue Regeneration</td>
<td>Organ Damage</td>
<td>Panigrahy et al. 2013</td>
</tr>
<tr>
<td></td>
<td>Endoplasmic Reticular Stress</td>
<td>Organ Damage</td>
<td>Bettaieb et al. 2013</td>
</tr>
<tr>
<td>Central Nervous System</td>
<td>Reduced Protein Aggregation</td>
<td>Alzheimer’s</td>
<td>Poli et al., 2013</td>
</tr>
<tr>
<td></td>
<td>(Prion)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Reduced Nerve Damage</td>
<td>Parkinsonism</td>
<td>Qin et al., 2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Seizure Resolution</td>
<td>Inceoglu et al., 2013; Hung et al., 2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stroke</td>
<td>Dorrance et al., 2005; Shaik et al. 2013</td>
</tr>
<tr>
<td>Adipose</td>
<td>Adipogenesis</td>
<td>Obesity</td>
<td>Da Taeye et al., 2010; Zha et al., 2014</td>
</tr>
<tr>
<td>Pancreas</td>
<td>Glucose Regulation</td>
<td>Diabetes</td>
<td>Luo et al., 2010; Chen et al., 2013</td>
</tr>
<tr>
<td>Tumors</td>
<td>Metastasis</td>
<td>Cancer</td>
<td>Panigraphy et al., 2012; Zhang et al., 2014b</td>
</tr>
</tbody>
</table>
Table 2. Experimentally important substrates of epoxide hydrolases. Epoxide hydrolases convert the 3-membered cycle ether of the epoxide in a downhill reaction adding water to generate a 1,2- or vicinal diol. Historically, a number of substrates have been experimentally important for both characterizing epoxide hydrolases and studying their physiologic importance. Kinetic studies using these substrates have primarily been performed only in a few species, so care must be taken when generalizing results across species.

![Epoxide hydrolase reaction diagram]

<table>
<thead>
<tr>
<th>Name</th>
<th>Structure</th>
<th>Primary Hydrolyzing Enzyme</th>
</tr>
</thead>
<tbody>
<tr>
<td>Styrene Oxide</td>
<td>![Styrene Oxide structure]</td>
<td>mEH and sEH</td>
</tr>
<tr>
<td>trans-β-Ethyl-Styrene Oxide</td>
<td>![trans-β-Ethyl-Styrene Oxide structure]</td>
<td>sEH</td>
</tr>
<tr>
<td>Allylbenzene Oxide</td>
<td>![Allylbenzene Oxide structure]</td>
<td>mEH and sEH</td>
</tr>
<tr>
<td>cis-Stilbene Oxide (CSO)</td>
<td>![cis-Stilbene Oxide structure]</td>
<td>mEH</td>
</tr>
<tr>
<td>trans-Stilbene Oxide (TSO)</td>
<td>![trans-Stilbene Oxide structure]</td>
<td>sEH</td>
</tr>
<tr>
<td>trans-Diphenylpropene Oxide (t-DPPO)</td>
<td>![trans-Diphenylpropene Oxide structure]</td>
<td>sEH</td>
</tr>
<tr>
<td>Cyano(6-methoxy-naphthalen-2-yl)methyl trans-[(3-phenyloxiran-2-yl)methyl] carbonate (CMNPO)</td>
<td>![Cyano(6-methoxy-naphthalen-2-yl)methyl trans-[(3-phenyloxiran-2-yl)methyl] carbonate structure]</td>
<td>sEH</td>
</tr>
<tr>
<td>Leukotoxin</td>
<td>![Leukotoxin structure]</td>
<td>sEH</td>
</tr>
<tr>
<td>11,12-Epoxyeicosatrienoic Acid (11,12-EET)</td>
<td>![11,12-Epoxyeicosatrienoic Acid structure]</td>
<td>sEH</td>
</tr>
<tr>
<td></td>
<td>Structure</td>
<td>Enzyme(s)</td>
</tr>
<tr>
<td>----------------------</td>
<td>-----------</td>
<td>-----------</td>
</tr>
<tr>
<td><strong>19,20-Epoxydocosapentaenoic Acid (19,20-EpDPE)</strong></td>
<td><img src="image1" alt="Structure" /></td>
<td>sEH</td>
</tr>
<tr>
<td><strong>Juvenile Hormone III (JH3)</strong></td>
<td><img src="image2" alt="Structure" /></td>
<td>JHEH, sEH</td>
</tr>
<tr>
<td><strong>5,6-Cholesterol Epoxide</strong></td>
<td><img src="image3" alt="Structure" /></td>
<td>ChEH</td>
</tr>
</tbody>
</table>
Figure 3

JH I

Methoprene (ZR515)

R 2-0458
Figure 4

A

\[ ^{3}\text{H}OH \xrightarrow{\text{EH}} ^{3}\text{H}OH \xrightarrow{\text{sEH}} \text{OH} \]

petroleum ether soluble  water soluble  iso-octane soluble  methanol-water soluble

B

\[ \text{CMNPO} \xrightarrow{\text{sEH}} \text{spontaneous} \xrightarrow{\text{spontaneous}} \text{fluorescent} \xrightarrow{\text{spontaneous}} \]

C

\[ \text{ACPU} \xrightarrow{\text{sEH}} \text{FRET} \]
Figure 5

Early Inhibitors
High Potency, Low Solubility, Poor PK

First Generation Inhibitors
High Potency, Increased Solubility, Poor PK

Second Generation Inhibitors
High Potency, Increased Solubility, Improved PK

Third Generation Inhibitors
Multi-Target Engagement
Figure 6

GSK 2256294A

Triclocarban

AR9281

TPPU

$t$-TUCB